Potent preclinical activity of HexaBody-DR5/DR5 in relapsed and/or refractory multiple myeloma. - van der Horst HJ; Gelderloos AT; Chamuleau MED; Breij ECW; Zweegman S; Nijhof IS; Overdijk MB; Mutis T (Blood advances, 2021)